Study Exclusion reasons Remarks Reference(s)
CloroCOVID19, 2020 randomized controlled trial inadequate or absent control group This paper reports partial results from an unplanned interim analysis.Efficacy and safety criteria do not appear to have ever been assessed on the same number of patients (denominators are different for almost every criterion and are less than the number of patients randomized). Compared to the registration record, the patient eligibility criteria were changed.

Borba JAMA Netw Open 2020; 3:e208857 10.1001/jamanetworkopen.2020.8857

Mayla Borba for CloroCovid-19 Team medRxiv 2020.04.07.20056424

 
ChiCTR2000029975, 0 single-arm not relevant study design  
ChiCTR2000029826 (Cancelled by the investigator), 0 randomized controlled trial cancelled by investigator  
Duke university (Hydroxychloroquine), 2020 randomized controlled trial cancelled by investigator  
Duke University hydroxychloroquine, 0 randomized controlled trial cancelled by investigator  
Million, 2020 single-arm no control group

Million Travel Med Infect Dis 2020; :101738 10.1016/j.tmaid.2020.101738

 
Mohana, 2020 retrospective cohort (claims database) no control group

Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031

 
Barbosa, 2020 retrospective cohort other the only document variable for this study is a copy of a submission to NEJM. It is impossible to verify the veracity of this document. The paper was submitted apr 4th and since this date ther is no publication in NEJM or in other media (included preprint server).  
Mallat, 2020 retrospective cohort other inapropriate statistical analysis. Time to events analyszed with means without taken into account the censure due to death or lost to follow-up

Jihad Mallat, Fadi Hamed, Maher Balkis, Mohamed A Mohamed, Mohamad Mooty, Asim Malik, Ahmad Nusair, Fernanda Bonilla medRxiv 2020.04.27.20082180 10.1101/2020.04.27.20082180

 
Mehra, 2020 retrospective cohort other the paper was retracted by 3 authors on June 4, 2020

Mehra MR Lancet 2020 May 22;S0140-6736(20)31180-6. 10.1016/S0140-6736(20)31180-6

Mehra MR Lancet 2020 Jun 13;395(10240):1820. 10.1016/S0140-6736(20)31324-6

 
Guerin, 2020 non randomized controlled trial other no binary endpoints

Guérin, Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1).

 
Kanran M, 2020 randomized controlled trial other randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls

sultan mehmood kamran medRxiv 10.1101/2020.07.30.20165365

 
Alberici, 2020 retrospective cohort other HCQ efficacy or safety evaluation wasn't a prespecified endpoint

Alberici F Kidney Int 2020 Jul;98(1):20-26. 10.1016/j.kint.2020.04.030